Cargando…
Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to Octo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884919/ https://www.ncbi.nlm.nih.gov/pubmed/33607252 http://dx.doi.org/10.1016/j.cmi.2021.02.008 |
_version_ | 1783651514612449280 |
---|---|
author | Klein, Hadar Asseo, Kim Karni, Noam Benjamini, Yuval Nir-Paz, Ran Muszkat, Mordechai Israel, Sarah Niv, Masha Y. |
author_facet | Klein, Hadar Asseo, Kim Karni, Noam Benjamini, Yuval Nir-Paz, Ran Muszkat, Mordechai Israel, Sarah Niv, Masha Y. |
author_sort | Klein, Hadar |
collection | PubMed |
description | OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to October 2020). Patients were recruited via social media and word to mouth and were interviewed up to 4 times, depending on reports of their unresolved symptoms. Inclusion criteria required participants to be residents of Israel aged 18 years or older, with positive COVID-19 real-time PCR results and nonsevere symptoms. The onset, duration, severity and resolution of symptoms were analysed. RESULTS: A total of 44% (45/103), 41% (42/103), 39% (40/103) and 38% (39/103) of patients experienced headache, fever, muscle ache and dry cough as the first symptom respectively. Smell and taste changes were experienced at 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± standard deviation (SD)) after disease onset respectively. Among prevalent symptoms, fever had the shortest duration (5.8 ± 8.6 days), and taste and smell changes were the longest-lasting symptoms (17.2 ± 17.6 and 18.9 ± 19.7 days; durations censored at 60 days). Longer recovery of the sense of smell correlated with the extent of smell change. At the 6-month follow-up, 46% (47/103) of the patients had at least one unresolved symptom, most commonly fatigue (22%, 23/103), smell and taste changes (15%, 15/103 and 8%, 8/103 respectively) and breathing difficulties (8%, 8/103). CONCLUSIONS: Long-lasting effects of mild COVID-19 manifested in almost half of the participants reporting at least one unresolved symptom after 6 months. |
format | Online Article Text |
id | pubmed-7884919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78849192021-02-16 Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients Klein, Hadar Asseo, Kim Karni, Noam Benjamini, Yuval Nir-Paz, Ran Muszkat, Mordechai Israel, Sarah Niv, Masha Y. Clin Microbiol Infect Original Article OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to October 2020). Patients were recruited via social media and word to mouth and were interviewed up to 4 times, depending on reports of their unresolved symptoms. Inclusion criteria required participants to be residents of Israel aged 18 years or older, with positive COVID-19 real-time PCR results and nonsevere symptoms. The onset, duration, severity and resolution of symptoms were analysed. RESULTS: A total of 44% (45/103), 41% (42/103), 39% (40/103) and 38% (39/103) of patients experienced headache, fever, muscle ache and dry cough as the first symptom respectively. Smell and taste changes were experienced at 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± standard deviation (SD)) after disease onset respectively. Among prevalent symptoms, fever had the shortest duration (5.8 ± 8.6 days), and taste and smell changes were the longest-lasting symptoms (17.2 ± 17.6 and 18.9 ± 19.7 days; durations censored at 60 days). Longer recovery of the sense of smell correlated with the extent of smell change. At the 6-month follow-up, 46% (47/103) of the patients had at least one unresolved symptom, most commonly fatigue (22%, 23/103), smell and taste changes (15%, 15/103 and 8%, 8/103 respectively) and breathing difficulties (8%, 8/103). CONCLUSIONS: Long-lasting effects of mild COVID-19 manifested in almost half of the participants reporting at least one unresolved symptom after 6 months. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-05 2021-02-16 /pmc/articles/PMC7884919/ /pubmed/33607252 http://dx.doi.org/10.1016/j.cmi.2021.02.008 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Klein, Hadar Asseo, Kim Karni, Noam Benjamini, Yuval Nir-Paz, Ran Muszkat, Mordechai Israel, Sarah Niv, Masha Y. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title | Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title_full | Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title_fullStr | Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title_full_unstemmed | Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title_short | Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients |
title_sort | onset, duration and unresolved symptoms, including smell and taste changes, in mild covid-19 infection: a cohort study in israeli patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884919/ https://www.ncbi.nlm.nih.gov/pubmed/33607252 http://dx.doi.org/10.1016/j.cmi.2021.02.008 |
work_keys_str_mv | AT kleinhadar onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT asseokim onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT karninoam onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT benjaminiyuval onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT nirpazran onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT muszkatmordechai onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT israelsarah onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients AT nivmashay onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients |